Welcome to our dedicated page for Aspire Biopharma Holdings news (Ticker: ASBP), a resource for investors and traders seeking the latest updates and insights on Aspire Biopharma Holdings stock.
Aspire Biopharma Holdings, Inc. (Nasdaq: ASBP) is a biotechnology and biopharmaceutical company centered on a patent-pending sublingual delivery platform for drugs and supplements. The ASBP news feed on Stock Titan aggregates coverage of the company’s clinical, regulatory, commercial and capital markets developments, giving readers a focused view of how Aspire’s strategy is progressing over time.
Company press releases describe a lead program in fast-acting, high-dose sublingual aspirin (OTASA) for the emergency treatment of suspected acute myocardial infarction, supported by pilot clinical data and FDA pre‑IND feedback under a 505(b)(2) pathway. News items also cover Aspire’s broader pipeline plans, which include reformulating approved drugs such as erectile dysfunction medications and semaglutide using its sublingual technology.
Beyond pharmaceuticals, Aspire Biopharma reports commercial activities around BUZZ BOMB™, a proprietary sublingual caffeine supplement marketed through its Buzz Bomb Caffeine Company LC subsidiary. News updates highlight product launches, manufacturing scale-up, e‑commerce initiatives, sampling campaigns and brand partnerships with high‑profile endurance athletes.
Investors following ASBP news can also track key corporate events disclosed by the company, such as Nasdaq listing compliance matters, reverse stock split decisions, patent filings, additions to the scientific team and participation in industry conferences like CPHI Frankfurt and virtual equity events. Together, these updates offer insight into Aspire Biopharma’s efforts to advance its sublingual platform, secure partnerships, expand consumer offerings and manage its public listing and financing arrangements. Bookmark this page to review new ASBP headlines, official announcements and related market commentary in one place.
Aspire Biopharma (Nasdaq:ASBP) subsidiary Buzz Bomb Caffeine Company signed a strategic brand management and distribution agreement with Blue Shark Beverages, effective February 1, 2026, to expand BUZZ BOMB™ retail placement across Southern California.
The rollout debuts in Palm Springs and Coachella Valley, then phases into Los Angeles and San Diego, targeting resorts, hotels, casinos, festival channels and broader retail outlets.
Aspire Biopharma (Nasdaq:ASBP) has signed an agreement with Microsize to support development of a 162 mg sublingual aspirin powder for emergency treatment of suspected acute myocardial infarction. The collaboration targets optimized drug product for an upcoming clinical trial and a planned Section 505(b)(2) NDA submission near end of 2026.
The clinical study will compare serum thromboxane B2 inhibition in 32 healthy volunteers versus two chewed 81 mg aspirin tablets; Microsize will provide cGMP micronization and particle‑engineering services to advance formulation and commercial manufacturing readiness.
Aspire Biopharma (Nasdaq:ASBP) announced filing a provisional patent application with the USPTO for the first-ever sublingual powder formulation of clopidogrel.
The filing covers a sublingual delivery system intended to improve clopidogrel pharmacokinetics by enabling absorption under the tongue, potentially increasing bioavailability and reducing or eliminating gastric irritation associated with oral tablets. Aspire plans to pursue commercialization via the FDA 505(b)(2) pathway and positions this program alongside its other reformulation efforts, including an investigational acetylsalicylic acid 162 mg sublingual powder (OTASA) intended for emergency myocardial infarction treatment.
Aspire Biopharma (NASDAQ:ASBP) announced delivery of two million units of its flagship caffeine supplement BUZZ BOMB™ on January 22, 2026, and strategic inventory of 100,000 20-packs now available to meet demand. The rollout includes a modernized brand identity, redesigned high-impact packaging, an emphasis on 50mg precise dosing and near-instant sublingual absorption, and a new e-commerce storefront. Aspire plans an aggressive growth push via expanded digital marketing, influencer partnerships, DTC optimization, and evaluation of retail and wholesale channels to scale the consumer business.
Aspire Biopharma (NASDAQ:ASBP) announced a comprehensive brand redesign for its flagship caffeine product, BUZZ BOMB™ on January 21, 2026. The initiative includes a new logo, a mobile‑optimized e-commerce website at https://buzzbombcaffeine.com, and redesigned packaging with a vibrant aesthetic to emphasize rapid, sustained focus and sublingual delivery.
The website offers a streamlined shopping experience, product information, promotions, and educational content. Management says the redesign aims to improve customer engagement, showcase the product's capabilities, and position BUZZ BOMB for growth.
Aspire Biopharma (NASDAQ:ASBP) filed a provisional patent application for a first-ever sublingual powder formulation of alprazolam, aiming to improve bioavailability and accelerate onset versus oral tablets. The filing covers a sublingual delivery system designed to absorb alprazolam under the tongue to bypass first-pass metabolism and potentially shorten onset from about 30 minutes to minutes.
The company said it plans a Phase 1 clinical trial in mid-2026 and intends to pursue commercialization via the FDA 505(b)(2) pathway. Aspire framed this program as part of a broader pipeline of reformulated approved therapeutics targeting patients needing rapid relief or who have difficulty swallowing.
Aspire Biopharma (NASDAQ:ASBP) announced a 1-for-40 reverse stock split of its common stock effective 12:01 a.m. ET on January 16, 2026, with split-adjusted trading beginning at market open on January 16, 2026. The split reduces outstanding shares from approximately 158.8 million to approximately 4.0 million (fractions excluded). The board approved the 1-for-40 ratio after stockholder authorization for a 1-for-5 to 1-for-40 range at the November 4, 2025 meeting. The company will file a Certificate of Amendment on January 15, 2026 and will continue trading under ticker ASBP with a new CUSIP 738920 206. The reverse split is being implemented to help ensure compliance with The Nasdaq Capital Market's minimum bid price requirement. Fractional shares will be rounded up to the nearest whole share at the participant level; no fractional shares will be issued.
Aspire Biopharma (Nasdaq: ASBP) completed a Type B pre-IND meeting with the FDA on January 7, 2026, receiving written feedback that supports a Section 505(b)(2) NDA filing in H2 2026 after a planned clinical trial.
The company will run a multicenter crossover study in 32 healthy volunteers comparing OTASA 162 mg sublingual powder vs. two chewed 81 mg aspirin tablets, measuring serum thromboxane B2 (TxB2) inhibition. Pilot data showed faster ASA absorption, TxB2 inhibition within two minutes, and no reported adverse events. Management said the FDA alignment de-risks the regulatory path and could support a breakthrough therapy request.
Aspire Biopharma (Nasdaq: ASBP) announced on December 18, 2025 that elite ultra-runner and Ironman champion Ashley Paulson is joining as global Brand Ambassador for BUZZ BOMB®, Aspire's sublingual caffeine product.
Paulson's credentials include 130+ marathons, 25+ Ironman-distance triathlons, multiple ultra triathlons, two 281.2-mile events, 6+ 100-mile races, Badwater 135 Women’s Champion (2022) and Overall Champion (2023). Aspire says Paulson will lead digital campaigns, exclusive training content, and represent BUZZ BOMB at major endurance events in 2026. BUZZ BOMB is positioned as near-instant sublingual caffeine for rapid energy without digestive upset. Paulson's social reach is listed as ~174,000 Instagram, 23,000 TikTok, and 12,000 Facebook followers.
Aspire Biopharma (Nasdaq: ASBP) received a notice from the Nasdaq Hearings Panel granting an extension to continue its Nasdaq listing, subject to conditions after the Company's transfer to the Nasdaq Capital Market.
The company will transfer its common stock listing effective at market open on December 15, 2025, retain the symbol ASBP, and must demonstrate compliance with the Bid Price Rule (Rule 5550(a)(2)) by January 30, 2026 and the Equity Rule (Rule 5550(b)(1)) by February 17, 2026. Management said it expects to cure the bid-price and market-value deficiencies and is working to recapitalize the balance sheet.